进展型多发性硬化中的血液神经丝轻链:两项随机对照试验的事后分析
该研究对EXPAND(继发进展型多发性硬化,SPMS)和INFORMS(原发进展型多发性硬化,PPMS)两项安慰剂对照3期试验进行事后盲法分析,共检测1452例SPMS和378例PPMS患者的血浆神经丝轻链(pNfL)。基线高pNfL(≥30 pg/mL)与更高的3个月和6个月残疾进展风险、更早的轮椅依赖、认知下降及更高脑萎缩率相关;pNfL在辛波莫德或芬戈莫德治疗患者中较低。
要点
- 基线pNfL≥30 pg/mL与SPMS和PPMS未来残疾进展及脑萎缩相关。
- pNfL与残疾进展的关联独立于是否存在急性疾病活动。
- 辛波莫德或芬戈莫德治疗患者pNfL水平低于安慰剂组。
核心结论
- pNfL在组水平上与未来临床和放射学残疾进展特征相关。
- pNfL可被治疗降低,可能是进展型多发性硬化研究中有意义的结果指标。
研究设计与样本
- 对两项安慰剂对照3期研究(EXPAND:继发进展型多发性硬化,辛波莫德;INFORMS:原发进展型多发性硬化,芬戈莫德)进行事后盲法分析。
- 采用单分子阵列(Homebrew Simoa)免疫分析法检测所有同意探索性生物标志物分析患者储存的EDTA血浆样本中的pNfL。
- 基线pNfL分为高(≥30 pg/mL)和低(<30 pg/mL)两组。
主要发现
- 分析SPMS患者1452例的4185份样本和PPMS患者378例的1172份样本。
- 基线pNfL几何均值SPMS为32.1 pg/mL,高于PPMS的22.0 pg/mL(p < 0.0001)。
- 两项研究中,基线pNfL较高均与年龄较大、EDSS评分较高、更多钆增强病灶和更高T2病灶负荷相关(均p < 0.05)。
- 高 vs 低基线pNfL与确认的3个月残疾进展风险显著更高相关:SPMS风险增加32%,HR 1.32(95%CI 1.09-1.61);PPMS风险增加49%,HR 1.49(95%CI 1.05-2.12);6个月残疾进展:SPMS风险增加26%,HR 1.26(95%CI 1.01-1.57);PPMS风险增加48%,HR 1.48(95%CI 1.01-2.17)。
- 高 vs 低基线pNfL与更早的轮椅依赖相关:SPMS风险增加50%,HR 1.50(95%CI 0.96-2.34);PPMS风险增加197%,HR 2.97(95%CI 1.44-6.10);与认知下降相关:SPMS风险增加41%,HR 1.41(95%CI 1.09-1.84);与更高脑萎缩率相关(第24个月平均变化:SPMS -0.92;PPMS -1.39)。
关键数值与推荐
- 基线pNfL高定义为≥30 pg/mL,低定义为<30 pg/mL。
- SPMS中高 vs 低基线pNfL的3个月确认残疾进展HR 1.32(95%CI 1.09-1.61),6个月HR 1.26(95%CI 1.01-1.57)。
- PPMS中高 vs 低基线pNfL的3个月确认残疾进展HR 1.49(95%CI 1.05-2.12),6个月HR 1.48(95%CI 1.01-2.17)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: To investigate the potential of plasma neurofilament light (pNfL) as a biomarker of disease progression and treatment response in progressive multiple sclerosis (PMS) with and without acute disease activity. METHODS: A post hoc blinded analysis of pNfL levels in 2 placebo-controlled, phase 3 studies in secondary progressive multiple sclerosis (SPMS; EXPAND) and primary progressive multiple sclerosis (PPMS; INFORMS) using siponimod and fingolimod, respectively, as active compounds was performed. pNfL levels were quantified using a single molecule array (Homebrew Simoa) immunoassay from stored ethylenediaminetetraacetic acid (EDTA) plasma samples of all patients who consented for exploratory biomarker analysis in either study; pNfL levels were divided into high (≥30 pg/mL) and low (<30 pg/mL) at baseline. We investigated the association of pNfL levels with disability progression, cognitive decline, and brain atrophy and their sensitivity to indicate treatment response through clinical measures. RESULTS: We analyzed pNfL in 4,185 samples from 1,452 patients with SPMS and 1,172 samples from 378 patients with PPMS. Baseline pNfL levels were higher in SPMS (geomean 32.1 pg/mL) than in PPMS (22.0 pg/mL; p < 0.0001). In both studies, higher baseline pNfL levels were associated with older age, higher Expanded Disability Status Scale score, more Gd+ lesions, and higher T2 lesion load (all p < 0.05). Independent of treatment, high vs low baseline pNfL levels were associated with significantly higher risks of confirmed 3-month (SPMS [32%], hazard ratio [95% CI] 1.32 [1.09-1.61]; PPMS [49%], 1.49 [1.05-2.12]) and 6-month disability progression (SPMS [26%], 1.26 [1.01-1.57]; PPMS [48%], 1.48 [1.01-2.17]), earlier wheelchair dependence (SPMS [50%], 1.50 [0.96-2.34]; PPMS [197%], 2.97 [1.44-6.10]), cognitive decline (SPMS [41%], 1.41 [1.09-1.84]), and higher rates of brain atrophy (mean change at month 24: SPMS, -0.92; PPMS, -1.39). Baseline pNfL levels were associated with future disability progression and the degree of brain atrophy regardless of presence or absence of acute disease activity (gadolinium-enhancing lesions or recent occurrence of relapses before baseline). pNfL levels were lower in patients treated with siponimod or fingolimod vs placebo-treated patients and higher in those having experienced disability progression. DISCUSSION: pNfL was associated with future clinical and radiologic disability progression features at the group level. pNfL was reduced by treatment and may be a meaningful outcome measure in PMS studies. TRIAL REGISTRATION INFORMATION: EXPAND (ClinicalTrials.gov identifier: NCT01665144) and INFORMS (ClinicalTrials.gov identifier: NCT00731692).
引用
- Leppert D, Kropshofer H, Häring DA, et al. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials. Neurology. 2022. PMID: 35379762. doi:10.1212/WNL.0000000000200258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。